Merit Medical Systems, Inc. (MMSI) Stock Analysis

57.0/100
Hold Not Halal Healthcare
Price $86.63
Market Cap $5.19B
52-Week Change -0.88%

Is MMSI a good investment?

Merit Medical Systems, Inc. (MMSI) has a Plutrex AI rating of 57.0/100 as of November 12, 2026, indicating a Hold consensus. The stock is not classified as halal-compliant. Key strength: Analyst target dramatically upgraded to $113.50 (from $102.00, +11.3%) while stock price fell 4.5% to $88.07 — this creates 28.9% upside to consensus, a material improvement in risk/reward from the prior report's 10.6% upside; combined with P/E compression from 38.01x to 33.07x (-13%), the valuation regime has meaningfully improved. Main concern: Structural forward growth deficit persists: 5-year EPS growth estimate of 9.5% trails industry 12.3% by 22.4%; even with the Q3 2026 beat, the forward consensus has not been materially revised upward yet — until EPS estimates for FY2026-2027 are revised above the 7-10% range, the PEG of 3.47 (even at a 29% discount to industry) reflects a stock that requires continued execution beats to avoid multiple compression.

Investment Summary

Merit Medical Systems (MMSI) at $88.07 is a well-run medical device company trading at a materially improved but still elevated valuation following a 4.5% price decline and a dramatic 11.3% upward revision in analyst consensus target (from $102.00 to $113.50). The key metrics: P/E of 33.07x (down from 38.01x two weeks ago), PEG of 3.47 (down from 4.21), and analyst target of $113.50 implying 28.9% upside. The bull case is meaningfully better than 14 days ago — the upside/downside ratio has improved from a catastrophic 0.54x to approximately 2.1x using the entry zone math. However, structural concerns persist: forward EPS growth of 7.3% next year and 9.5% over 5 years still does not justify a 33x P/E in isolation. The news backdrop is genuinely positive — 21.7% YoY EPS growth reported for Q3 2026, 9% organic constant-currency revenue growth, a tuck-in acquisition (Solo Pace, Inc.), and real-world AVF data presentation at a major innovation conference. The combination of price decline + analyst target increase + strong Q3 execution is a meaningful regime change from the prior hold/avoid posture.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
74/100
Growth Potential
38/100
Valuation
38/100
Profitability
72/100
Debt Management
78/100
Analyst Sentiment
72/100
Technical Momentum
52/100
Insider Confidence
55/100
News Sentiment
88/100

Fundamental Analysis

MMSI's fundamentals are solid but not exceptional. Gross margin of 49.4% (vs. industry 45.87%, +354bps) demonstrates durable pricing power. Net margin of 9.93% (vs. industry 7.20%, +273bps) is the standout profitability metric — MMSI converts revenue to profit 38% more efficiently than the average peer. Operating margin of 13.9% is modestly above peers (13.29%). ROE of 9.78% (vs. industry 7.62%) beats peers but remains low in absolute terms for a 3.02x Price-to-Book stock — requires 15-20%+ ROE to fully justify. Debt-to-equity of 0.47 (vs. industry 0.52) is conservative. Cash of $503.6M and FCF of $204.2M provide substantial optionality. The growth picture is the structural weakness: revenue growth of 8.4% vs. industry 12.9% (-34.9%), forward EPS next year at 7.3% vs. industry 9.8% (-25.6%), 5-year EPS growth at 9.5% vs. industry 12.3% (-22.4%). HOWEVER, Q3 2026 actual EPS growth of 21.7% YoY significantly outperformed the 7.3% forward estimate, raising the question of whether analyst estimates are too conservative. P/E of 33.07x vs. industry 42.02x (a 21.3% discount) and PEG of 3.47 vs. industry 4.89 (a 29.1% discount) confirm MMSI is relatively cheaper than peers, though still elevated in absolute terms. Fair value DCF estimate remains in the $55-65 range on conservative assumptions, but with the analyst target now at $113.50 (consensus of multiple analysts), there is meaningful upside potential if Q3's 21.7% EPS growth signals analyst estimate revisions.

News Sentiment

Merit Medical Systems is quietly having a moment — and Wall Street is finally taking notice. The Utah-based medical device maker just delivered a standout third quarter for 2026, reporting a remarkable 21.7% jump in earnings per share compared to the same period last year, alongside 9% organic constant-currency revenue growth (headline: 'Merit Medical Reports Third Quarter 2026 Results'). That's the kind of execution that makes investors sit up straight. But the bigger news may be what's happening on the innovation front. Merit Medical researchers stepped onto a major stage to present real-world data from the AVF Cohort of the WRAP Global Registry (headline: 'Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Re...'), showcasing the company's push into cutting-edge vascular therapies. Meanwhile, the company made a strategic move into cardiac care by acquiring Solo Pace, Inc., expanding its cardiac therapies platform (headline: 'Merit Medical Acquires Solo Pace, Inc.'). Analysts have responded by sharply raising their price target to $113.50, up from $102.00 just two weeks ago — a 11% upgrade. Even a neutral take from Zacks (headline: 'Here's Why You Should Retain MMSI Stock in Your Portfolio for Now') acknowledges the company's solid position. The story here is a company that's executing better than expected, innovating in high-growth medical niches, and buying strategically — all while trading at a 21% discount to its medical device peers on an earnings basis.

Risk Assessment

PRIMARY RISK: If Q3 2026's 21.7% EPS growth does not trigger meaningful analyst estimate revisions, the stock reverts to its structural PEG of 3.47 on 7-9% growth, potentially warranting further P/E compression toward 25-28x (fair for the growth rate), implying downside to $67-73. SECONDARY RISK: Tariff/China headwinds cited in news could compress the best-in-class net margin (9.93%) toward industry average (7.20%), destroying the valuation premium thesis. STOP-LOSS LOGIC: $77.00 stop (12.6% below entry at $85.75) corresponds to approximately 32x prior-year earnings — below this level the market is signaling fundamental deterioration beyond valuation compression. UPSIDE SCENARIO: If Q3 beat triggers analyst revisions to 12-15% EPS growth (bringing MMSI in line with industry peers), the PEG would re-rate toward industry average of 4.89, implying a price of $107-115, consistent with the new $113.50 analyst target. MITIGATION: Conservative 3.0% position size limits portfolio exposure; entry zone of $83-88.50 enters at a P/E of 31-33x (more reasonable than the prior 38x) and captures the new risk/reward inflection.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is MMSI a halal stock?

No, Merit Medical Systems, Inc. (MMSI) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for MMSI?

Merit Medical Systems, Inc. (MMSI) has a Plutrex AI rating of 57.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is MMSI a good investment?

According to Plutrex AI, MMSI has a Hold rating (57.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in MMSI?

US stocks like MMSI can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in MMSI?

Plutrex AI identifies the main risks for MMSI by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about MMSI

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open MMSI in ElBarake